Anti-Mouse CD1d Antibody (1B1) 

Anti-Mouse CD1d Antibody (1B1) is an antibody targeting mouse CD1d (K_d=12.5 nM). By inserting into the lipid-binding groove of CD1d, Anti-Mouse CD1d Antibody (1B1) overlaps with the binding sites of type I and type II NKT cell receptors (TCR), thereby effectively blocking TCR-mediated interactions. Anti-Mouse CD1d Antibody (1B1) activates antigen-presenting cells such as dendritic cells and macrophages, induces them to release IL-12p70, and increases the levels of key cytokines including IL-12, IFN-γ and IFN-α in mouse serum. Anti-Mouse CD1d Antibody (1B1) can be used in studies related to renal cancer, breast cancer and colon adenocarcinoma. When combined with anti-DR5 or anti-CD137 antibodies and chemotherapeutic drugs, Anti-Mouse CD1d Antibody (1B1) exhibits significant tumor inhibitory and even eradication effects in mice^[1][2].

Rat IgG2b

Rat IgG2b kappa, Isotype Control

Mouse

Anti-Mouse CD1d Antibody (1B1) (overnight) binds to insect cell-expressed mouse CD1d presenting endogenous lipid, sulfatide, or GT1b with similar affinity, with K_d values ranging from 10.2 to 12.6 nM^[2].
Anti-Mouse CD1d Antibody (1B1) (2 h, overnight) blocks Type I NKT 1.2 and Type II NKT XV19 hybridoma activation by α-GalCer and sulfatide, respectively, but does not block activation by α-GSA[26,P5p]; 1B1 IgG blocks activation of both hybridomas by all three tested glycolipids, including α-GSA[26,P5p], at concentrations as low as 1.5 μg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (intraperitoneal injection; 3 administrations; dose: 12.5-400 μg) induces dose-dependent clearance of established R331 renal cell carcinoma tumors in BALB/c mice. This effect is completely dependent on CD8⁺ T cells, IFN-γ, IL-12 and CD1d, and partially dependent on NK cells^[1].
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (i.p.; 200 μg; 3 administrations) efficiently eliminates established 4T1 breast cancer in BALB/c mice, and remains effective even when administration is delayed until the tumors reach a large volume; this therapy is completely dependent on CD8⁺ T cells and IFN-γ, independent of type I NKT cells, and only partially dependent on NK cells and IL-12^[1].
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (200 μg; intraperitoneal injection; 3 administrations) effectively eliminates established CT26L5 colon adenocarcinoma in BALB/c mice. This effect is completely dependent on CD8⁺ T cells and IFN-γ, independent of type I NKT cells or NK cells, and only partially dependent on IL-12^[1].
The 1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (200 μg; i.p.; administered 3 times on days 19, 23, and 27) exhibits better efficacy than the combination therapy of Doxorubicin (HY-15142A) + anti-CD1d + anti-CD137 in eradicating established late-stage 4T1 breast cancer in BALB/c mice^[1].
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (i.p.; 200 μg; administered 3 times on days 19, 23 and 27) exhibits superior efficacy over the combination therapy of Gemcitabine (HY-17026) + anti-CD1d + anti-CD137 and other tested chemoimmunotherapies in eliminating established advanced CT26L5 colon adenocarcinoma in BALB/c mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

12479  [NCBI]

P11609

CD1d

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[Anti-Mouse CD1d Antibody (1B1)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Teng MW, et al. CD1d-based combination therapy eradicates established tumors in mice. J Immunol. 2009 Aug 1;183(3):1911-20.

  [2]. Ying G, et al. Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1. J Biol Chem. 2019 Aug 30;294(35):12947-12956.